Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the characteristics of ALLO-715, a targeted chimeric antigen receptor (CAR) T-cell therapy currently being assessed in the Phase I UNIVERSAL trial (NCT04093596). ALLO-715 is the first allogenic off-the-shelf donor-derived B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy for patients with multiple myeloma. Dr Hari additionally explains potential complications of donor-derived T-cells, such as graft-versus-host disease (GvHD), as well as mitigation strategies, such as administration of ALLO-647 as part of the lymphodepletion regimen. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

свернуть